Francesco Maisano, clinic director at the University Hospital Zurich, recently led a team of cardiac surgeons and cardiologists in for the first time repairing a leaky tricuspid valve using a new catheter technology.

St. Jude Medical Inc. announced the U.S. clearance and launch of the company’s new PressureWire X Guidewire fractional flow reserve (FFR) measurement system. The latest generation of the PressureWire Guidewire system is designed to offer improved shapeability and better shape retention aimed at reducing vessel trauma, with the accuracy and simplicity physicians expect when treating patients during percutaneous coronary intervention (PCI), especially those with complex anatomies.

The 2016 Nobel Prize in chemistry was recently awarded to three scientists who developed miniaturized machines that are smaller than the width of a human hair. This science and engineering feat was recognized because it may help take chemistry and engineering into a new dimension in the coming years. This includes the development of micro-robots that may one day be injected into patients so they can independently support the body’s fight against a variety of diseases, including tissue repair or cleansing the circulatory system of atherosclerotic deposits.

International Symposium on Endovascular Therapy (ISET)

ACVP SouthCoast Health Cardio Conference


The transradial revolution is one of the fastest growing trends in cardiology. Compared to the femoral access technique, transradial access is associated with reductions in access-site complications, bleeding complications and overall morbidity.[1-3] Furthermore, the radial approach in ST-elevated myocardial infarction (STEMI) patients has been associated with significant reduction in major adverse events during follow up.[4] Technology and techniques are constantly evolving and expanding in the field of transradial procedures, including the drapes we employ.


International Academy of Cardiology Annual Scientific Sessions

Mercator MedSystems recently announced that 13-month data from the DANCE trial was presented during a late-breaking scientific session at the Vascular Interventional Advances (VIVA) Annual Conference 2016. DANCE is a prospective, multicenter, single-arm study designed to assess the clinical performance of the localized delivery of a generic steroid, dexamethasone, to the tissues around arteries that have been injured during endovascular interventions, using Mercator’s proprietary Bullfrog Micro-Infusion Device.

Subscribe Now